TB-500 Peptide

TB-500 peptide, also referred to as synthetic Thymosin Beta 4 (Tβ4), is a laboratory-derived version of the naturally occurring protein Thymosin beta 4. This native protein is found within cells of the thymus and is encoded by the TMSB4X gene. Research has suggested that TB-500 may exhibit similar biological potential to its natural counterpart, with proposed mechanisms including the promotion of angiogenesis, enhanced wound healing processes, and possible influences on tumour cell activity and hair growth.

In addition to being highly water-soluble and relatively low in molecular weight, TB-500 is a peptide composed of 43 amino acids and is present in significant concentrations within wound fluid, particularly in association with blood platelets. It has been suggested that the peptide may demonstrate anti-inflammatory properties and could support neurological recovery, as well as contributing to healing processes within the spinal cord, cardiac tissue, and the epidermis.(1)

Overview

TB-500 peptide, also known as thymosin β(4), contains a specific peptide segment—(17)LKKTETQ(23)—which functions as its active site. Researchers consider this region to be particularly relevant in processes such as actin binding, cellular migration, and wound repair.(2) The full amino acid sequence of TB-500 is:
Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH.

Actins are fundamental proteins that form a core component of the cellular cytoskeleton, contributing to both structural integrity and essential functions such as movement. Actin is considered critical in maintaining these cellular processes. Thymosin beta-4, and by extension TB-500, is believed to interact with actin by binding to globular actin (G-actin), which serves as the precursor to filamentous actin (F-actin). This interaction may limit the conversion of G-actin into F-actin—a process referred to as actin sequestration—thereby increasing the availability of G-actin within the cell. By inhibiting F-actin formation, thymosin beta-4 may alter cytoskeletal structure, potentially influencing cell mobility and morphological adaptation. These effects are thought to be relevant in physiological and pathological conditions where cell movement is essential, including tissue repair, regeneration, and cancer progression through metastasis.(3)

In addition to its intracellular presence, thymosin beta-4 has also been identified in extracellular environments such as blood plasma and wound exudates. Early-stage research involving vascular cells suggests that, when present outside the cell, thymosin beta-4 may influence processes like cellular motility and angiogenesis. (11,12) It has been proposed that these effects may occur through interactions with ATP synthase enzymes located on the cell surface, which play a key role in cellular energy production. These observations point toward a broader functional profile for thymosin beta-4, encompassing both intracellular and extracellular mechanisms of action.

Chemical Makeup
  • Molecular Formula: C212H350N56O78S
  • Molecular Weight: 4963 g/mol
  • Other Known Titles: Thymosin Beta 4
Research and Clinical Studies
TB-500 Peptide and Inflammation

Tβ4, and by extension TB-500, is proposed to potentially elevate levels of microRNA-146a (miR-146a), which may act as a regulatory suppressor of certain cellular signalling pathways—particularly those linked to inflammation-related cytokines, including interleukin-1 receptor-associated kinase 1 (IRAK1) and tumour necrosis factor receptor-associated factor 6 (TRAF6). Researchers investigating this interaction have suggested that this pathway may represent one of the peptide’s mechanisms of action. More specifically, the study noted that the “transfection of anti-miR-146a nucleotides reversed the inhibitory effect of Tβ4 on IRAK1 and TRAF6,” indicating a potential regulatory role mediated through miR-146a. As a result, it is proposed that TB-500 may exert anti-inflammatory effects through modulation of these signalling pathways.(4)

TB-500 Peptide and Acute Wounds

In 1999, a study was conducted using wounded murine models that were administered TB-500, a synthetic form of Thymosin Beta 4.(5) Four days following administration, researchers reported that the TB-500-treated models demonstrated an approximate 41% increase in re-epithelialisation compared to control subjects that received saline. By day seven, the wounds in the TB-500 group were observed to have contracted by at least 11% more than those in the control group.

Based on these findings, it was suggested that TB-500 may promote angiogenesis and enhance collagen deposition, thereby contributing to an increased rate of wound healing. The authors concluded that their observations “suggest that Tβ4 is a potent wound healing factor with multiple activities,” highlighting its potential role across several mechanisms involved in tissue repair.

TB-500 Peptide and Chronic Wounds

Research investigations were conducted across a range of animal models, including healthy rats and mice, diabetic mice, aged mice, and steroid-treated rats. Each of these subjects was inflicted with full-thickness punch wounds and subsequently administered the TB-500 peptide. The findings indicated that TB-500 appeared to enhance the rate of wound healing across all models, irrespective of the underlying conditions present in each group.

In addition to these preclinical observations, phase 2 clinical trials were also undertaken in relation to stasis and pressure ulcers. Results from these studies suggested that TB-500 may accelerate the healing process by up to one month, further supporting its potential role in promoting tissue repair across various conditions.(6)

TB-500 Peptide and Heart Cells

Pulmonary hypertension is regarded by researchers as a progressive cardiovascular condition in which the pulmonary arteries restrict blood flow from the right ventricle. This restriction may lead to increased pulmonary vascular resistance and elevated pressure, potentially progressing to right ventricular failure. In experimental studies, TB-500 was reported to exhibit activity along the Notch3–Col3A–CTGF gene axis in monocrotaline (MCT)-induced murine models. This interaction appeared to result in a significant reduction in right ventricular hypertrophy within the study setting.(7)

Drawing from broader research on Tβ4, TB-500 has also been suggested to influence cardiac cell regeneration. Preliminary findings indicate that the peptide may improve the resilience of myocardial cells under hypoxic conditions and promote angiogenesis, which could support the repair of cardiac tissue. Researchers have further proposed that cardiac fibroblasts may have the potential to differentiate into cardiomyocyte like cells under certain conditions.(8) Additionally, it has been suggested that combining TB-500 with cardiac reprogramming approaches may work synergistically to reduce cardiac damage and enhance regeneration by activating intrinsic repair mechanisms within the heart.

Further experimental work involving murine models with ligated coronary arteries indicated that TB-500 may increase the activity of integrin-linked kinase (ILK) and protein kinase B (Akt) within cardiac tissue. These findings suggest a possible improvement in early cardiomyocyte survival and overall cardiac function.(9) Moreover, research has indicated that TB-500 may support the migration of myocardial and endothelial cells in the developing fetal heart, with evidence suggesting that this functional capacity may also be retained in adult cardiomyocyte.

TB-500 and Hair Follicle Growth

In 2003, studies were conducted on murine models to investigate the potential role of TB-500 in hair growth.(10) Following administration of the peptide, histological examination of skin tissue suggested that TB-500 appeared to increase the number of hair shafts and hair follicles, indicating a potential stimulatory effect on hair growth.

Further analysis using real-time PCR and Western blotting techniques revealed differences in mRNA expression between TB-500-treated and control groups. The findings indicated elevated mRNA and protein levels in the TB-500 group, which were suggested to be associated with the observed increase in hair growth.(10)

TB-500 and Blood Vessel Formation

It has been hypothesised that TB-500 may influence angiogenesis through a series of molecular interactions. This proposition is based on studies utilising lentiviral vectors to induce TB-500 over expression in human umbilical vein endothelial cells (HUVEC), alongside investigations in murine critical limb ischaemia (CLI) models.(13) To further explore the underlying biological mechanisms, researchers incorporated inhibitors such as DAPT, which targets the Notch signalling pathway, and BMS, which affects the NF-κB pathway, within both HUVEC and murine CLI experiments.

The effects of TB-500 on angiogenesis and cellular migration were assessed using a range of laboratory techniques. These included MTT assays to evaluate cell viability, as well as tube formation and wound healing assays to measure angiogenic and migratory capacity. Additional molecular analyses—such as Western blotting, reverse transcription, quantitative PCR, immunofluorescence, and immunohistochemistry—were employed to examine the expression of angiogenesis-related markers and components of the Notch and NF-κB pathways. Findings suggested that TB-500 may enhance HUVEC viability, angiogenesis, and migration, while also increasing the expression of key factors including angiopoietin-2 (Ang2), TEK receptor tyrosine kinase 2 (Tie2), vascular endothelial growth factor A (VEGFA), NOTCH1 intracellular domain (N1ICD), Notch receptor 3 (Notch3), NF-κB, and phosphorylated p65.

Similar patterns were observed in the muscle tissue of murine CLI models, where elevated expression of CD31, α-smooth muscle actin (α-SMA), Ang2, Tie2, VEGFA, N1ICD, and p-p65 was reported, suggesting a regulatory influence of TB-500 on these molecular targets. Notably, the use of DAPT and BMS appeared to inhibit the effects of TB-500, indicating that its pro-angiogenic activity may be mediated through interactions with the Notch and NF-κB signalling pathways. Furthermore, the observed reversal of DAPT and BMS activity by TB-500 may reinforce its role in modulating these pathways, supporting the broader hypothesis that Tβ4 contributes to angiogenesis through regulation of these critical molecular systems.

TB-500 and Corneal Tissues

Studies have suggested that TB-500 may influence cytokine production, potentially contributing to accelerated healing in corneal wound models.(14) Following injury, there is some indication that the peptide may increase the expression of IL-1β and IL-6 mRNA within the corneal tissue of murine models. Additionally, in cases of alkali-induced injury, TB-500 exposure appeared to reduce the expression of chemoattractants such as MIP-2 and KC, which are involved in recruiting polymorphonuclear neutrophils (PMNs). This reduction may lead to decreased PMN infiltration within the cornea.

With respect to inflammatory signalling, TB-500 is theorised to interact with NFκB pathways, potentially contributing to anti-inflammatory effects. The peptide has also been proposed to exhibit anti-apoptotic properties. Observations from cellular models suggest that overexpression of TB-500 may increase cellular growth rates, reduce baseline apoptosis, and enhance resistance to cell death-inducing factors. In corneal epithelial cells, TB-500 may inhibit apoptosis by interfering with caspase activity and limiting the release of pro-apoptotic proteins such as Bcl-2 from the mitochondria.

The proposed anti-apoptotic mechanisms of TB-500 may involve suppression of early cell death signalling and activation of survival pathways, including the Akt kinase, potentially through interactions with PINCH and integrin-linked kinase. These findings suggest that TB-500 may exert its effects through multiple molecular pathways. However, it is important to note that these mechanisms remain theoretical and require further validation through continued research.

TB-500 peptide is available for research and laboratory purposes only. Please speak to our friendly research team to find out more and for sourcing options.

References:

  1. Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-75.  doi: 10.1016/bs.vh.2016.04.005.  Epub 2016 May 24.

  2. Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012 Nov 23;1265:57-69.  doi: 10.1016/j.chroma.2012.09.043.  Epub 2012 Sep 23.

  3. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039.  PMID: 18480812.

  4. Santra, M., Zhang, Z. G., Yang, J., Santra, S., Santra, S., Chopp, M., & Morris, D. C. (2014). Thymosin β4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway. The Journal of biological chemistry, 289(28), 19508–19518.  https://doi.org/10.1074/jbc.M113.529966

  5. Katherine M. Malinda et.al, Thymosin β4 Accelerates Wound Healing, Journal of Investigative Dermatology, Volume 113, Issue 3, 1999, Pages 364-368, ISSN 0022-202X.

  6. Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012 Oct.

  7. Wei C, Kim IK, Li L, Wu L, Gupta S. Thymosin Beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. PLoS One. 2014 Nov 20;9(11):e110598.

  8. Srivastava, D., Ieda, M., Fu, J., & Qian, L. (2012). Cardiac repair with thymosin β4 and cardiac reprogramming factors. Annals of the New York Academy of Sciences, 1270, 66–72. https://doi.org/10.1111/j.1749-6632.2012.06696.x

  9. Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472.  https://doi.org/10.1038/nature03000

  10. Gao, Xy., Hou, F., Zhang, Zp. et al. Role of thymosin beta 4 in hair growth. Mol Genet Genomics 291, 1639–1646 (2016).

  11. Huff, T., Müller, C. S., Otto, A. M., Netzker, R., & Hannappel, E. (2001). beta-Thymosins, small acidic peptides with multiple functions. The international journal of biochemistry & cell biology, 33(3), 205–220.  https://doi.org/10.1016/s1357-2725(00)00087-x

  12. Freeman, K. W., Bowman, B. R., & Zetter, B. R. (2011). Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 25(3), 907–915.  https://doi.org/10.1096/fj.10-169417

  13. Lv, S., Cai, H., Xu, Y., Dai, J., Rong, X., & Zheng, L. (2020). Thymosin-β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway. International journal of molecular medicine, 46(4), 1347–1358.  https://doi.org/10.3892/ijmm.2020.4701

  14. Sosne, G., Qiu, P., & Kurpakus-Wheater, M. (2007). Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clinical ophthalmology (Auckland, N.Z.), 1(3), 201–207.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

TB-500 Peptide